1.345  0.065 (5.08%)		10-09 15:48
Open: 1.27 High: 1.55 Volume: 1,657,407		Pre. Close: 1.28 Low: 1.27 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	1.85	1-year :	2.35
Resists	First :	1.59	Second :	2.01
Pivot price	1.33
Supports	First :	0.89	Second :	0.74
MAs	MA(5) :	1.27	MA(20) :	1.37
	MA(100) :	1.61	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	23.7	D(3) :	16.5
RSI	RSI(14): 49.3
52-week	High :	5.5	Low :	0.76

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GELS ] has closed below upper band by 42.9%. Bollinger Bands are 60.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.3 - 1.31	1.31 - 1.32
Low:	1.24 - 1.25	1.25 - 1.26
Close:	1.27 - 1.28	1.28 - 1.29

Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.

Thu, 09 Oct 2025
Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound - The Manila Times

Thu, 09 Oct 2025
Gelteq partners with Melbourne Health to develop bowel cancer prevention gel By Investing.com - Investing.com South Africa

Mon, 08 Sep 2025
Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market - Stocktwits

Sun, 07 Sep 2025
Gelteq Shares Surge Amid Bioequivalence Study Announcement - timothysykes.com

Sat, 06 Sep 2025
Gelteq Stock Surges Amid Antihistamine Study Announcement - timothysykes.com

Wed, 06 Aug 2025
https://seekingalpha.com/pr/20169476-gelteq-announces-agreement-with-idt-australia-to-secure-dedicated-new-product-development-and - Stocktwits

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	10 (M)
Shares Float	4 (M)
Held by Insiders	56.8 (%)
Held by Institutions	1 (%)
Shares Short	212 (K)
Shares Short P.Month	77 (K)

EPS	-0.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.95
Profit Margin	0 %
Operating Margin	-657 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	305.1 %
Gross Profit (p.s.)	0.02
Sales Per Share	0.03
EBITDA (p.s.)	-0.24
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-3.86
PEG Ratio	0
Price to Book value	0.69
Price to Sales	35.83
Price to Cash Flow	-3.2

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.